tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GSK’s Momelotinib Study: A Potential Breakthrough for Low-risk Myelodysplastic Syndrome
Company AnnouncementsGSK’s Momelotinib Study: A Potential Breakthrough for Low-risk Myelodysplastic Syndrome
2d ago
GSK
GSK Advances Share Buyback Program with Latest Purchase
PremiumCompany Announcements
GSK Advances Share Buyback Program with Latest Purchase
2d ago
GSK Advances in Atopic Dermatitis Treatment with Long-Term Study
PremiumCompany Announcements
GSK Advances in Atopic Dermatitis Treatment with Long-Term Study
3d ago
GSK
GSK’s Belimumab Study: A Promising Update for SLE Treatment
PremiumCompany Announcements
GSK’s Belimumab Study: A Promising Update for SLE Treatment
3d ago
GSK
GSK’s Promising Study on Belimumab for Lung Disease: A Potential Game-Changer?
PremiumCompany Announcements
GSK’s Promising Study on Belimumab for Lung Disease: A Potential Game-Changer?
3d ago
GSK
GSK’s Promising Update on Multiple Myeloma Treatment Study
PremiumCompany AnnouncementsGSK’s Promising Update on Multiple Myeloma Treatment Study
3d ago
GSK
GSK’s Promising Hepatitis B Study: A Potential Game-Changer for Investors
Premium
Company Announcements
GSK’s Promising Hepatitis B Study: A Potential Game-Changer for Investors
3d ago
GSK
GSK’s New SLE Drug Study: What Investors Need to Know
Premium
Company Announcements
GSK’s New SLE Drug Study: What Investors Need to Know
3d ago
GSK
GSK Executes Share Buyback to Strengthen Capital Structure
PremiumCompany Announcements
GSK Executes Share Buyback to Strengthen Capital Structure
3d ago
Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
PremiumThe Fly
Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
4d ago
GSK
PFE
GSK Enhances Buyback Program with New Share Purchase
PremiumCompany Announcements
GSK Enhances Buyback Program with New Share Purchase
4d ago
GSK’s AtDvance Study: A Long-Term Look at Atopic Dermatitis Treatment
PremiumCompany Announcements
GSK’s AtDvance Study: A Long-Term Look at Atopic Dermatitis Treatment
5d ago
GSK
GSK’s Belimumab Study: A Potential Game-Changer for Systemic Lupus Erythematosus Treatment
PremiumCompany AnnouncementsGSK’s Belimumab Study: A Potential Game-Changer for Systemic Lupus Erythematosus Treatment
5d ago
GSK
GSK’s Promising Phase 3 Study on Belimumab for Interstitial Lung Disease
Premium
Company Announcements
GSK’s Promising Phase 3 Study on Belimumab for Interstitial Lung Disease
5d ago
GSK
GSK Announces Share Transactions by Senior Executive
Premium
Company Announcements
GSK Announces Share Transactions by Senior Executive
5d ago
GSK’s Wendy Becker Appointed Chair of Sony Board
PremiumCompany Announcements
GSK’s Wendy Becker Appointed Chair of Sony Board
5d ago
GSK says FDA approves Benlysta Autoinjector for kids with active lupus nephritis
PremiumThe Fly
GSK says FDA approves Benlysta Autoinjector for kids with active lupus nephritis
5d ago
GSK
GSK Expands Share Buyback Program with Recent Purchase
PremiumCompany Announcements
GSK Expands Share Buyback Program with Recent Purchase
5d ago
GSK Directors Increase Shareholdings, Signaling Confidence
PremiumCompany Announcements
GSK Directors Increase Shareholdings, Signaling Confidence
6d ago
GSK Directors Show Confidence with Share Purchases
PremiumCompany AnnouncementsGSK Directors Show Confidence with Share Purchases
6d ago
GSK announces EMA has accepted for review the MAA for use of linerixibat
Premium
The Fly
GSK announces EMA has accepted for review the MAA for use of linerixibat
6d ago
GSK
GSK’s Linerixibat for PBC Pruritus Gains EMA Review Acceptance
Premium
Company Announcements
GSK’s Linerixibat for PBC Pruritus Gains EMA Review Acceptance
6d ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >